LONDON UK companies are expected to try and offload a record amount of risk linked to their pension schemes in 2019 as growth in life expectancy eases and interest rates rise, making deals more attractive for insurance firms.
AstraZeneca said on Friday its immunotherapy drug Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares.
British builder Kier Group said on Friday it would meet its expectations for the full year on the back of a strong second half, suggesting that it was able to shrug off a hit to the construction sector from Britain's imminent exit from the European Union.
British engineer Smiths Group plans to spin off its healthcare business to focus on industrial technology, two months after a 7 billion pound ($9.1 billion) deal to merge it with U.S.-based ICU Medical collapsed.
Euronext's acquisition of the Irish Stock Exchange and a higher number of companies listing helped the pan-European exchange beat quarterly profit estimates, although it warned some of its recent growth initiatives had failed.
Hiscox on Monday warned of slowing growth in the final three months of the year, sending shares in the Lloyd's of London underwriter down almost 8 percent and eclipsing a rise in nine-month gross written premiums.
Embattled drugmaker Indivior said on Thursday the hit to revenue this year from a cheap copy of its top-selling opium addiction drug would be less than feared, as cost cutting helped it to deliver a 22 percent rise in quarterly profit.
* Shares give back early gains to trade lower
(Adds details on the company's drugs, background, comments)
Britain's competition watchdog on Wednesday cleared exchange group CME's 3.9 billion pound ($4.96 billion) deal to buy Michael Spencer's NEX trading platform.
* Ex-CEO Shahenshah to appeal conviction- solicitor
(Adds Shahenshah to appeal, SFO spokeswoman comment)